[Abstract] Current studies on the age-related development of metabolic dysfunction and frailty are each day in more evidence. It is known, as aging progresses, nicotinamide adenine dinucleotide (NAD + ) levels decrease in an expected physiological process. Recent studies have shown that a reduction in NAD + is a key factor for the development of age-associated metabolic decline. Increased NAD + levels in vivo results in activation of pro-longevity and health span-related factors. Also, it improves several physiological and metabolic parameters of aging, including muscle function, exercise capacity, glucose tolerance, and cardiac function in mouse models of natural and accelerated aging.
et al., 2009; Bai et al., 2011; Yoshino et al., 2011) . In previous publications, our laboratory has demonstrated that expression and activity of the NADase CD38 increases with age and that CD38 is required for the age-related NAD decline and mitochondrial dysfunction via a pathway mediated at least in part by regulation of SIRT3 activity (Camacho-Pereira et al., 2016) . We also identified CD38 as the main enzyme involved in the degradation of the NAD precursor nicotinamide mononucleotide (NMN) in vivo. That indicates that CD38 has a key role in the modulation of NAD-replacement therapy for aging and metabolic diseases (Camacho-Pereira et al., 2016). CD38 was originally identified as a cell-surface enzyme that plays a key role in several physiological processes such as immune response, inflammation, cancer, and metabolic disease (Frasca et Several different assays and methods have been described due to the great importance of monitoring NAD + and NADH cellular levels under various physiological conditions. Specifically two of them, ultraperformance liquid chromatography (UPLC)-mass spectroscopy assay and cycling assay have finality and both are equally sensitive and specific (Camacho-Pereira et al., 2016).
Our laboratory also further optimized and validated the cycling assay. We determined NAD + and NADH specific and does not detect any of the other nucleotides or NAD derivatives tested, including In regards to the cycling assay (pathway in which the main reaction happens), it takes NAD + and NADH present in the samples and they are coupled to both enzymes alcohol dehydrogenase (ADH) and diaphorase in a cycling assay. Every time NAD + or NADH cycles, it produces a molecule of resorufin, which is highly fluorescent. This fluorescence is directly captured by the multi-well fluorescence plate Considering either NAD + or NADH quantification, the only step that distinguishes those two is the extraction part. From Step A2 on, the process is the same for both NAD + and NADH. Copyright 2. To obtain the standard curve, dilute the 1 µM stock of NAD + in sodium phosphate buffer following Stock for ADH has to be 3400 U/ml.
Stock for Diaphorase has to be 100 U/ml.
2. Weigh the enzymes in a 1.5 ml tube for preparation of 1 ml solution. Check the amount of U/mg in the bottle being used as it might change depending on the lot number. 3. Remove bound NAD + from Diaphorase and ADH by diluting the enzymes in 30% (300 µl) of sodium phosphate buffer and 70% (700 µl) of 4% charcoal suspension for a total of 1 ml solution.
Gently mix the solution, and incubate it for 40 min at 37 °C. Mix gently every 10 min. 3. Prepare the reaction mix following Table 2 below, respecting the amount and the order in which each component has to be added. 3. Calculate the mass of protein (mg) present in the sample by dividing protein concentration (mg/ml) by volume of NaOH (ml) in which the pellet was re-suspended.
Divide the NAD + concentration obtained in
Step 2 by the mass of protein obtained in Step 3. This is the final result ( Figure 3B ).
5. Plot the results (nM/mg protein) in a graph.
6. Perform statistical analysis as needed.
www.bio-protocol.org/e2937 The primary stock solutions were stored at -80 °C and were prepared in silanized glass vials as follows:
NAD + (10 mg/ml in water) NADH (1 mg/ml in 0.01 N NaOH, pH 11.9) n-cyclohexyl benzamide (IS) (100 µg/ml in EtOH)
For working standards:
Working standards were prepared by dilution of the stock solution into the same solutions mentioned above. Daily standard samples were prepared by diluting above stocks 1:20 in water containing 500 ng/ml internal standard
